Q1 2019 13F Holders as of 31 Mar 2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Total 13F shares
-
25,936,719
-
Share change
-
+3,906,269
-
Total reported value
-
$926,454,784
-
Put/Call ratio
-
181%
-
Price per share
-
$35.72
-
Number of holders
-
161
-
Value change
-
+$145,772,798
-
Number of buys
-
74
-
Number of sells
-
57
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q1 2019
As of 31 Mar 2019,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
161 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
25,936,719 shares.
The largest 10 holders included
Versant Venture Management, LLC, NEA Management Company, LLC, ARK Investment Management LLC, EcoR1 Capital, LLC, WELLINGTON MANAGEMENT GROUP LLP, Abingworth LLP, WADDELL & REED FINANCIAL INC, Cormorant Asset Management, LP, CREDIT SUISSE AG/, and BB BIOTECH AG.
This page lists
162
institutional shareholders reporting positions in this security
for the Q1 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.